Lee & Ko successfully advised 2014 STIC M&A PEF established by STIC INVESTMENT INC on its acquisition of 5.35% shares in Amicogen Co., Ltd., a limited liability company conducting businesses in the development and sale of bio technology applied enzymes and advanced materials. Total price of the transaction was KRW 35,000,000,000 and the purchase price will be put to use by Amicogen’s acquisition price of interests in Shandong Lukang Record Pharmaceutical Co., Ltd (“LKR”), which is a business partner of Amicogen in China. Lee & Ko advised on all matters related to the 2014 STIC M&A PEF’s acquisition of Amicogen shares, as well as Acmicogen’s acquisition of LKR’s interest.